Gilead Pays ViiV $1.25B Plus Royalties To End HIV Patent Suit

By Hailey Konnath (February 1, 2022, 11:32 PM EST) -- Gilead has agreed to pay $1.25 billion plus royalties to GlaxoSmithKline venture ViiV Healthcare to settle claims Gilead infringed patents with its HIV drug, the companies announced Tuesday, a deal that comes less than a month after a trial in the high-profile case was delayed due to COVID-19....

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!